Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In 10 matched-pair cell lines [established at diagnosis (DX) and progressive disease (PD) from the same patients], BCL-2 expression in the DX and PD lines was comparable, suggesting that BCL-2 expression at diagnosis may provide a biomarker for neuroblastomas likely to respond to 4-HPR + ABT-199.
|
31484706 |
2019 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
GX15-070 (Obatoclax), a Bcl-2 family proteins inhibitor engenders apoptosis and pro-survival autophagy and increases Chemosensitivity in neuroblastoma.
|
31664947 |
2019 |
Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In SH-SY5Y neuroblastoma cell line expressing a high level of BCL-2 but low levels of MST2 and SAV1, siRNA-induced knockdown of BCL-2 restored the expression of MST2 and SAV1.
|
30867124 |
2019 |
Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We report that SH-SY5Y cells incubated with GMF and Aβ (1-42) promote mitochondrial fragmentation, by potentiating oxidative stress, mitophagy and shifts in the Bax/Bcl2 expression and release of cytochrome-c, and eventual apoptosis.
|
30949973 |
2019 |
Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Ectopic expression of LGP2 in NB cells significantly enhanced poly (I:C)-induced NB cell death associated with downregulation of MDA5, RIG-I, MAVS and Bcl-2, as well as upregulation of Noxa and tBid.
|
30179292 |
2018 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overall, our results demonstrate the therapeutic potential of CXCR4 inhibition in neuroblastoma treatment and provide a rationale to test combination therapies employing CXCR4 and BCL-2 inhibitors to increase the efficacy of these agents.<b>Significance:</b> These results provide a mechanistic rationale for combination therapy of CXCR4 and BCL-2 inhibitors to treat a common and commonly aggressive pediatric cancer.<i></i>.
|
29259008 |
2018 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In <i>MYCN</i>-amplified neuroblastoma, PUMA induction by GSK-J4 sensitized tumors to the B cell lymphoma 2 (BCL-2) inhibitor venetoclax, demonstrating that epigenetic-targeted therapies and BCL-2 homology domain 3 mimetics can be rationally combined to treat this high-risk subset of neuroblastoma.
|
29769286 |
2018 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
PCNP over-expression increased protein expressions of cleaved caspase-3, cleaved caspase-8, cleaved caspase-9, and cleaved poly adenosine diphosphate-ribose polymerase, as well as ratios of B-cell lymphoma-2 (Bcl-2)-associated X protein/Bcl-2 and Bcl-2-associated death promoter/B-cell lymphoma-extra large in human neuroblastoma cells, however PCNP knockdown exhibited reverse trends.
|
29716528 |
2018 |
Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
MAO-B inhibitors selegiline and rasagiline protect neurons via increase expression of anti-apoptotic Bcl-2 and pro-survival neurotrophic factors in human neuroblastoma SH-SY5Y and glioblastoma U118MG cell lines.
|
29279995 |
2018 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we investigated the roles of P53 and BCL2 family members in the protection of BDNF/TrkB from etoposide-induced NB cell death.
|
29959561 |
2018 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, these data strongly support the further evaluation of dual BCL2/MDM2 targeting as a therapeutic strategy in neuroblastoma.
|
28915653 |
2017 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To further explore whether S-nitrosylation of Bcl-2 involved in Mn-induced autophagy dysregulation, we treated human neuroblastoma (SH-SY5Y) cells with Mn and pretreated cells with 1400 W, a selective iNOS inhibitor.
|
28856835 |
2017 |
Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The results indicated that neuroblastoma cell and hEnSC viability is in good agreement with the level of Bcl2 and β-tubulin III gene expression; however, -BMHP-1 and -laminin nanofibers exhibited significantly higher cell viability eventually through Wnt/β-catenin signaling pathway as compared to others, respectively.
|
27389777 |
2017 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Nanoparticle delivery of curcumin induces cellular hypoxia and ROS-mediated apoptosis via modulation of Bcl-2/Bax in human neuroblastoma.
|
28702620 |
2017 |
Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Treatment with PBA effectively attenuated TDCIPP-induced ER stress and protected against apoptotic death in SH-SY5Y cells by inhibition of Bax expression and promotion of Bcl-2 expression.
|
27816613 |
2017 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using data from our large drug screen we predicted, and subsequently demonstrated, that MYCN-amplified neuroblastomas are sensitive to the BCL-2 inhibitor ABT-199.
|
26859456 |
2016 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, whole-genome transcriptome analysis revealed that BRG1 controls the expression of key elements of oncogenic pathways such as PI3K/AKT and BCL2, which offers a promising new combination therapy for high-risk NB.
|
26996667 |
2016 |
Neuroblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mechanistically treatment of NBs with small molecule inhibitors of EGFR (erlotinib, cetuximab) and ERK (U0126) increases Noxa expression and dephosphorylates Bim to promote Bim binding to Bcl(-)2.
|
25756510 |
2015 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, targeting Bcl-2 with small molecule inhibitor ABT-263 could be a novel strategy for treatment of neuroblastoma.
|
24891300 |
2014 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We showed that SART1 knockdown similarly sensitized Mcl1-dependent NB to ABT-737 and that triple knockdown of UBL5/PRPF8/SART1 phenocopied direct MCL1 knockdown, whereas having no effect on Bcl2-dependent NBs.
|
24556687 |
2014 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
LSD1 protein expression levels were assessed semi-quantitatively in specimens of NB and ganglioneuroblastoma (GNB), along with the apoptosis markers, Bcl-2 and Bax.
|
23816987 |
2013 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
By serendipity we cloned a variant of the anti-apoptotic Bcl2-family member Myeloid cell leukemia-1 (Mcl1) from human neuroblastoma and leukemia cells.
|
23872733 |
2013 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Human neuroblastoma cells (SH-SY5Y) were exposed to isatin at various concentrations (0, 50, 100, 200 μmol/l) for 48 h. Bcl-2 and Bax mRNA were analyzed via RT-PCR.
|
23376416 |
2013 |
Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models.
|
24009722 |
2013 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Identical results were obtained by treatment of the neuroblastoma cell lines with the small molecule BCL2 inhibitor ABT263, which is currently being clinically evaluated.
|
22366560 |
2012 |